Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
FIGHT-201 trial: what clinicians have said so far
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
- NCT02872714 ↗
- Completed
- Incyte Corporation
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on FIGHT-201 (pemigatinib in metastatic or unresectable urothelial carcinoma with FGF/FGFR alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FIGHT-201 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations - (FIGHT-201)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- UC (Urothelial Cancer)
- Interventions
- pemigatinib; pemigatinib
- Arms
- Cohort A-ID (Intermittent Dose) Pemigatinib · Experimental
- Cohort A-CD (Continuous Dose) Pemigatinib · Experimental
- Cohort B Pemigatinib · Experimental
- Enrollment
- 263
- Primary outcomes
- Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen
- Sponsor
- Incyte Corporation
- Start
- Jan 12, 2017
- Primary completion
- Feb 1, 2022
- Results posted
- Yes
- Registry record
- NCT02872714 · updated Aug 14, 2025
Publications
linked from the registry- Zhang C, Huang MN, Shan JQ, Hu ZJ, Li ZW, Liu JY. Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. Biochem Biophys Res Commun. 2024 Jan 8;691:149314. doi: 10.1016/j.bbrc.2023.149314. Epub 2023 Nov 24. PubMed 38039831
- Necchi A, Pouessel D, Leibowitz R, Gupta S, Flechon A, Garcia-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot Y. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Ann Oncol. 2024 Feb;35(2):200-210. doi: 10.1016/j.annonc.2023.10.794. Epub 2023 Nov 11. PubMed 37956738